Participated · Series B · Oct 2025

Lattice Medical develops resorbable, 3D-printed implantable devices for reconstruction of soft tissues such as in post-cancer breast and deep subcutaneous tissue reconstruction. The company plans to integrate a supercritical CO2 sterilization process into its industrial 3D-printing manufacturing chain to meet implantable-device sterility requirements while preserving material properties. It also intends to shorten production times, reinforce regulatory control, secure critical manufacturing steps, and offer sterilization services to third parties. Founded in 2017 by Julien Payen, the company holds 14 international patents. Financially, Lattice Medical raised approximately €2.15 million for the MEDCO2 project and previously completed a €43 million funding round in 2025. Clinically, it closed the first phase of its TIDE trial with 10 patients enrolled.

Participated · Equity · Sep 2025

Genoskin is a French-American contract research organization that leverages donated human skin and proprietary preservation technology to keep immunocompetent skin viable for up to seven days after surgery. The resulting ex vivo platforms generate rich multiomics datasets that are interpreted with AI and advanced bioinformatics to provide human-relevant insights into toxicity and efficacy. Supported by a strong IP portfolio, a reliable tissue-sourcing network and a scalable service model, the company already counts many major global pharmaceutical firms among its clients across biopharma, cosmetics, and cell- and gene-therapy sectors. Genoskin’s technology is particularly valuable for skin-related delivery routes such as injectables, including vaccines, and topically administered drugs. With its first $8.7 million funding round now closed, the company intends to double its workforce within three years and broaden its commercial footprint in Europe and Asia by 2026. Future plans include launching new immune-centric service offerings by 2027, developing biosimulation platforms and novel human immune models, and scaling production through industrial automation. Genoskin will expand manufacturing capacity at upgraded facilities in Salem, Massachusetts in 2026 and Toulouse, France in 2027, enabling doubled skin-model output and U.S. next-day delivery of fresh human mast cells.

Participated · Equity · Jul 2024

Bridge.audio offers a cloud-native workspace and marketplace (Sync Hub) for creators and music professionals to receive, store, share and discover audio using an internally developed descriptive AI trained on nearly a decade of data. The platform centralizes workflows that today rely on disparate tools (WeTransfer, Google Drive, Dropbox), improving collaboration and reducing the industry's digital footprint. Its Sync Hub marketplace, launched in January, connects rights-holders (labels, publishers, artists) with buyers and supervisors in film, advertising, TV and gaming. The company emphasizes responsible use of generative AI as a support to human creativity and to improve discoverability through advanced tagging and natural-language search. Bridge.audio reports more than 30,000 users since launch two years ago, with over 200 labels and publishers on the Sync Hub and roughly 120 buyers including Orange, Chanel, Louis Vuitton and TBWA. The team plans to open additional hubs focused on other segments (original music, A&R, promotion) to broaden marketplace coverage.

Participated · Seed · Oct 2023

Bon Vivant develops animal-free milk proteins by reprogramming yeast via precision fermentation to produce both whey and casein intended as B2B ingredients for food manufacturers. The company focuses exclusively on a supplier model rather than consumer products, aiming to provide multinational food companies with proteins that deliver functionality such as gelling, foaming and texturizing. It plans to scale production and obtain regulatory clearances—targeting U.S. clearance first with potential commercialization as soon as 2025, and expecting EU approval to take two to three years. The seed funding will be used to open a new Lyon lab capable of producing 40‑litre pre‑production samples to accelerate testing, trials, product development and IP generation. An early third‑party LCA modeled at 2,160 tonnes/year suggests potential reductions of ~97% GHG emissions, ~99% drinking water consumption and ~50% energy use versus cow’s milk. Bon Vivant says it will continue to use third‑party producers for the foreseeable future while progressing toward commercial scale supply for large dairy customers.

Participated · Seed · Apr 2022

Hemerion develops a combined therapeutic approach that pairs a drug, Pentalafen®, with a photonic device, the Heliance® Solution, to treat glioblastoma. Pentalafen® is administered before tumor resection and preferentially accumulates in tumor cells; after surgery the Heliance® illumination activates the drug to destroy residual cancer cells where light penetrates. Phase I trials conducted in 2017–2018 with CHU de Lille were published in 2021 and demonstrated safety, tolerability, and encouraging early efficacy signals. The company says the technology integrates into standard care alongside surgery, radiotherapy, and chemotherapy and was co‑designed with neurochirurgeons for use in the operating room. Hemerion is discussing Phase II trial setup with the FDA, targeting first patient inclusion in late 2023, and plans to explore extending the technology to other oncology indications. The company reports having raised more than €7M over the past two years and intends to pursue a Series A to fund the pivotal Phase II and III studies required for commercialisation. Hemerion Therapeutics develops a photochemical therapeutic platform (Heliance) that combines a tumor‑selective drug with targeted laser illumination to destroy cancer cells while sparing healthy tissue. The technology is designed as an add‑on to surgery to eliminate tumor cells in areas inaccessible to resection and has potential applications beyond glioblastoma. Hemerion has already initiated its clinical program with a first conclusive clinical trial and is conducting preclinical evaluations for other cancer indications. The company is actively engaging with the FDA to obtain IND clearance and plans a Phase II trial in the first half of 2023 in collaboration with Mount Sinai Hospital (10–15 patients) to validate safety. Financially, Hemerion completed a €3.55M seed fundraising to accelerate international clinical development and to strengthen regulatory, clinical and industrial resources, while preparing for a Series A in 2023.